A detailed history of Legal & General Group PLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Legal & General Group PLC holds 59,537 shares of PTGX stock, worth $2.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,537
Previous 50,686 17.46%
Holding current value
$2.65 Million
Previous $1.47 Million 40.65%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $218,265 - $308,014
8,851 Added 17.46%
59,537 $2.06 Million
Q1 2024

Jul 01, 2024

BUY
$21.79 - $32.15 $67,679 - $99,857
3,106 Added 6.53%
50,686 $1.47 Million
Q1 2024

May 14, 2024

BUY
$21.79 - $32.15 $49,920 - $73,655
2,291 Added 5.06%
47,580 $1.38 Million
Q4 2023

Feb 15, 2024

BUY
$14.05 - $23.44 $7,362 - $12,282
524 Added 1.17%
45,289 $1.04 Million
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $4,420 - $6,269
265 Added 0.6%
44,765 $746,000
Q2 2023

Aug 14, 2023

BUY
$18.02 - $29.36 $457,059 - $744,687
25,364 Added 132.55%
44,500 $1.23 Million
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $50,967 - $119,996
4,728 Added 32.82%
19,136 $440,000
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $8,228 - $12,488
1,118 Added 8.41%
14,408 $157,000
Q3 2022

Nov 14, 2022

SELL
$7.86 - $11.71 $38,010 - $56,629
-4,836 Reduced 26.68%
13,290 $112,000
Q2 2022

Aug 22, 2022

SELL
$7.06 - $25.52 $24,484 - $88,503
-3,468 Reduced 16.06%
18,126 $143,000
Q1 2022

May 16, 2022

BUY
$23.34 - $36.08 $7,702 - $11,906
330 Added 1.55%
21,594 $511,000
Q4 2021

Feb 14, 2022

BUY
$17.63 - $37.1 $11,142 - $23,447
632 Added 3.06%
21,264 $727,000
Q3 2021

Nov 15, 2021

BUY
$12.95 - $49.69 $104,519 - $401,047
8,071 Added 64.25%
20,632 $365,000
Q2 2021

Aug 12, 2021

BUY
$25.57 - $44.88 $51,549 - $90,478
2,016 Added 19.12%
12,561 $563,000
Q1 2021

May 17, 2021

BUY
$19.02 - $31.15 $4,431 - $7,257
233 Added 2.26%
10,545 $273,000
Q4 2020

Feb 12, 2021

BUY
$18.49 - $25.13 $123,809 - $168,270
6,696 Added 185.18%
10,312 $208,000
Q3 2020

Nov 13, 2020

SELL
$15.19 - $22.4 $1,610 - $2,374
-106 Reduced 2.85%
3,616 $71,000
Q2 2020

Aug 14, 2020

BUY
$6.19 - $18.84 $6,394 - $19,461
1,033 Added 38.42%
3,722 $66,000
Q1 2020

May 14, 2020

SELL
$5.4 - $9.22 $4,438 - $7,578
-822 Reduced 23.41%
2,689 $19,000
Q4 2019

Feb 13, 2020

BUY
$4.69 - $13.45 $1,997 - $5,729
426 Added 13.81%
3,511 $25,000
Q3 2019

Nov 13, 2019

BUY
$9.41 - $16.56 $5,222 - $9,190
555 Added 21.94%
3,085 $37,000
Q2 2019

Aug 14, 2019

BUY
$8.98 - $12.96 $22,719 - $32,788
2,530 New
2,530 $31,000
Q2 2018

Aug 10, 2018

SELL
$5.99 - $9.1 $13,207 - $20,065
-2,205 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$14.47 - $20.8 $31,906 - $45,864
2,205
2,205 $46,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.19B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.